Through several CHPA member company donations, 144 U.S. schools of pharmacy received over 100 different OTC medicines, medical devices, and dietary supplements to educate and prepare future pharmacists.
This week, the four leading trade associations representing the U.S. dietary supplement industry joined forces to urge Congress to take action to ensure consumer safety and provide legal clarity in the CBD product marketplace.
The Personal Care Products Council and Consumer Healthcare Products Association submitted comments to the U.S. Food & Drug Administration (FDA) in response to the Sunscreen Tentative Final Monograph.
The 2018 results from the National Institute on Drug Abuse and University of Michigan's annual drug abuse survey, Monitoring the Future, show that the percentage of teens using OTC cough medicine containing dextromethorphan to get high remains at three percent.
Yesterday, Pennsylvania Governor Tom Wolf signed into law HB 1951, legislation prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors.
In a study newly published in the medical journal Clinical Toxicology, “therapeutic misuse” of OTC combination products containing acetaminophen was infrequent and declined over a 10-year period.
CHPA applauds Colorado for enacting a law prohibiting the sale of over-the-counter (OTC) medicines containing the cough suppressant dextromethorphan (DXM) to minors this week.
CHPA applauds New Hampshire for becoming the 35th state to adopt the real-time, stop-sale technology called the National Precursor Log Exchange (NPLEx), a system used by retailers across the country to help prevent the illegal sale of pseudoephedrine.
CHPA applauds the U.S. House Ways and Means Health Subcommittee for today’s hearing, examining the benefits of consumer access to tax-preferred savings accounts, HSAs and FSAs.
